The global hemophilia market size reached US$ 13.0 Billion in 2023. Looking forward, the market is expected to reach US$ 31.2 Billion by 2032, exhibiting a growth rate (CAGR) of 10.2% during 2023-2032.
Hemophilia is an inherited medical disorder that affects the blood clotting process, wherein the blood clots abnormally. It results in spontaneous and excessive bleeding, easy bruising, and oozing after an injury, surgery, and dental procedures. It is caused by a hereditary lack of a coagulation factor that slows down blood clotting due to the deficiency of adequate blood-clotting proteins. It can be treated using medications, replacement therapy and injections of a clotting factor or plasma. Its treatment focuses on replacing missing proteins and preventing complications.
Additionally, they are increasingly funding research and development (R&D) activities due to the limited availability of treatment options. Furthermore, leading industry players are focusing on introducing technologically advanced diagnostic tools and therapies to enhance the efficacy and accuracy of hemophilia treatment, which is offering a favorable market outlook. Moreover, extensive investments in expanding the establishment of specialized hemophilia treatment centers (HTCs) across the globe are anticipated to drive the market.
2. What is the expected growth rate of the global hemophilia market during 2024-2032?
3. What are the key factors driving the global hemophilia market?
4. What has been the impact of COVID-19 on the global hemophilia market?
5. What is the breakup of the global hemophilia market based on the type?
6. What is the breakup of the global hemophilia market based on the treatment?
7. What is the breakup of the global hemophilia market based on the therapy?
8. What are the key regions in the global hemophilia market?
9. Who are the key players/companies in the global hemophilia market?
Hemophilia is an inherited medical disorder that affects the blood clotting process, wherein the blood clots abnormally. It results in spontaneous and excessive bleeding, easy bruising, and oozing after an injury, surgery, and dental procedures. It is caused by a hereditary lack of a coagulation factor that slows down blood clotting due to the deficiency of adequate blood-clotting proteins. It can be treated using medications, replacement therapy and injections of a clotting factor or plasma. Its treatment focuses on replacing missing proteins and preventing complications.
Hemophilia Market Trends:
The increasing number of hemophilic patients and rising occurrences of genetic abnormalities among individuals across the globe represents one of the key factors positively influencing the market. In addition, the rising diagnosis rate of the illness and the growing popularity of prophylactic treatment to cure hemophilia are offering lucrative growth opportunities to leading market players. Apart from this, governing agencies of various countries are organizing numerous campaigns to spread awareness about the benefits of early diagnosis and following appropriate procedures to facilitate the early screening of neonates, which is creating a positive outlook for the market.Additionally, they are increasingly funding research and development (R&D) activities due to the limited availability of treatment options. Furthermore, leading industry players are focusing on introducing technologically advanced diagnostic tools and therapies to enhance the efficacy and accuracy of hemophilia treatment, which is offering a favorable market outlook. Moreover, extensive investments in expanding the establishment of specialized hemophilia treatment centers (HTCs) across the globe are anticipated to drive the market.
Key Market Segmentation:
This report provides an analysis of the key trends in each sub-segment of the global hemophilia market report, along with forecasts at the global, regional and country level from 2024-2032. The report has categorized the market based on type, treatment, and therapy.Breakup by Type:
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Others
Breakup by Treatment:
- On-Demand
- Prophylaxis
Breakup by Therapy:
- Replacement Therapy
- ITI Therapy
- Gene Therapy
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.Key Questions Answered in This Report
1. What was the size of the global hemophilia market in 2023?2. What is the expected growth rate of the global hemophilia market during 2024-2032?
3. What are the key factors driving the global hemophilia market?
4. What has been the impact of COVID-19 on the global hemophilia market?
5. What is the breakup of the global hemophilia market based on the type?
6. What is the breakup of the global hemophilia market based on the treatment?
7. What is the breakup of the global hemophilia market based on the therapy?
8. What are the key regions in the global hemophilia market?
9. Who are the key players/companies in the global hemophilia market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Hemophilia Market
6 Market Breakup by Type
7 Market Breakup by Treatment
8 Market Breakup by Therapy
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Baxter International Inc.
- Bayer AG
- BioMarin Pharmaceutical Inc.
- CSL Behring (CSL Limited)
- F. Hoffmann-La Roche AG
- Grifols S.A.
- Kedrion S.p.A.
- Novo Nordisk A/S
- Octapharma AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | September 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 13 Billion |
| Forecasted Market Value ( USD | $ 31.2 Billion |
| Compound Annual Growth Rate | 10.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
